# | Title | Journal | Year | Citations |
---|
1 | Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma | Leukemia | 2008 | 787 |
2 | Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2015 | 458 |
3 | Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2021 | 265 |
4 | Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients | Blood | 2011 | 259 |
5 | Autologous stem cell transplantation for progressive multiple sclerosis: Update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database | Multiple Sclerosis Journal | 2006 | 206 |
6 | Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group | Blood | 2008 | 190 |
7 | Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure | Blood | 2008 | 164 |
8 | Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study | Blood | 2011 | 161 |
9 | Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma | Blood | 2009 | 157 |
10 | Allogeneic Stem-Cell Transplantation May Overcome the Adverse Prognosis of Unmutated VH Gene in Patients With Chronic Lymphocytic Leukemia | Journal of Clinical Oncology | 2005 | 137 |
11 | The number of donor CD3+ cells is the most important factor for graft failure after allogeneic transplantation of CD34+ selected cells from peripheral blood from HLA-identical siblings | Blood | 2001 | 118 |
12 | New prognostic markers in chronic lymphocytic leukemia | Blood Reviews | 2008 | 118 |
13 | Chronic lymphocytic leukemia and autoimmunity: a systematic review | Haematologica | 2011 | 117 |
14 | A different ontogenesis for chronic lymphocytic leukemia cases carrying stereotyped antigen receptors: molecular and computational evidence | Leukemia | 2010 | 109 |
15 | The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma | Annals of Oncology | 2006 | 107 |
16 | Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling | Blood | 2013 | 107 |
17 | Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status | Leukemia | 2001 | 105 |
18 | Smoldering (Asymptomatic) Multiple Myeloma: Current Diagnostic Criteria, New Predictors of Outcome, and Follow-Up Recommendations | Journal of Clinical Oncology | 2010 | 101 |
19 | Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia | Leukemia | 2002 | 100 |
20 | Extramedullary multiple myeloma escapes the effect of thalidomide | Haematologica | 2004 | 100 |
21 | Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia | Clinical Cancer Research | 2015 | 98 |
22 | Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation | Annals of Oncology | 2013 | 89 |
23 | How I treat refractory CLL | Blood | 2006 | 85 |
24 | Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL‐IPI | American Journal of Hematology | 2017 | 79 |
25 | Transplantation for multiple myeloma: who, when, how often? | Blood | 2003 | 76 |
26 | Monoclonal Gammopathy of Undetermined Significance: Predictors of Malignant Transformation and Recognition of an Evolving Type Characterized by a Progressive Increase in M Protein Size | Mayo Clinic Proceedings | 2007 | 76 |
27 | Unrelated Cord Blood Transplantation | Transplantation | 2013 | 66 |
28 | Lestaurtinib Inhibition of the JAK/STAT Signaling Pathway in Hodgkin Lymphoma Inhibits Proliferation and Induces Apoptosis | PLoS ONE | 2011 | 64 |
29 | Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis | Blood | 2014 | 62 |
30 | Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation | Bone Marrow Transplantation | 2007 | 55 |
31 | Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation | Bone Marrow Transplantation | 2017 | 53 |
32 | Single Antigen–Mismatched Unrelated Hematopoietic Stem Cell Transplantation Using High-Dose Post-Transplantation Cyclophosphamide Is a Suitable Alternative for Patients Lacking HLA-Matched Donors | Biology of Blood and Marrow Transplantation | 2018 | 50 |
33 | Alemtuzumab as Treatment of Steroid-Refractory Acute Graft-versus-Host Disease: Results of a Phase II Study | Biology of Blood and Marrow Transplantation | 2009 | 45 |
34 | Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents | Cytokine | 2008 | 41 |
35 | Simultaneous diagnosis of hairy cell leukemia and chronic lymphocytic leukemia/small lymphocytic lymphoma: a frequent association? | Leukemia | 2002 | 38 |
36 | Incidence and Clinical Significance of Bcl-2 / IgH Rearrangements in Follicular Lymphoma | Leukemia and Lymphoma | 2003 | 37 |
37 | Bortezomib: A valuable new antineoplastic strategy in multiple myeloma | Acta Oncológica | 2005 | 35 |
38 | Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation | Bone Marrow Transplantation | 2017 | 35 |
39 | Multiple cell cycle regulator alterations in Richter's transformation of chronic lymphocytic leukemia | Leukemia | 2002 | 34 |
40 | Treatment of Chronic Lymphocytic Leukemia: Achieving Minimal Residual Disease–Negative Status As a Goal | Journal of Clinical Oncology | 2005 | 34 |
41 | Life expectancy of young adults with follicular lymphoma | Annals of Oncology | 2015 | 31 |
42 | Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration | European Journal of Haematology | 2006 | 30 |
43 | Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center | Cancer | 2018 | 30 |
44 | Thalidomide in refractory and relapsing multiple myeloma | Seminars in Oncology | 2001 | 29 |
45 | Chronic lymphocytic leukaemia: a short overview | Annals of Oncology | 2008 | 29 |
46 | Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT | Journal of Hematology and Oncology | 2021 | 27 |
47 | Myelofibrosis with myeloid metaplasia in adult individuals 30 years old or younger: presenting features, evolution and survival | European Journal of Haematology | 2001 | 26 |
48 | Survivin expression in the progression of chronic myeloid leukemia: A sequential study in 16 patients | Leukemia and Lymphoma | 2005 | 26 |
49 | Clinical implications of ZAP-70 expressionin chronic lymphocytic leukemia | Cytometry Part B - Clinical Cytometry | 2006 | 26 |
50 | Management of Complications in Multiple Myeloma | Seminars in Hematology | 2009 | 26 |